Revenue
2022
XORTX Therapeutics Inc. (XRTX)
Price$2.38Cached quote
Net income
2019
2020
2021
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2019
2020
2021
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | — | — | — |
| Research & development | — | — | — | — | $853,124 | $277,455 | $39,897 |
| Net income | — | — | — | — | −$1.7M | −$1.3M | −$629,576 |
| Basic EPSper basic share | — | — | — | — | -CA$0.17 | -CA$0.19 | -CA$0.12 |
| Diluted EPSper diluted share | — | — | — | — | CA$9,847,641.00 | CA$6,664,025.00 | CA$5,359,444.00 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
CITADEL ADVISORS LLC | 23.12K |
StoneX Group Inc. | 16.37K |
ROYAL BANK OF CANADA | 732 |
NATIONAL BANK OF CANADA /FI/ | 162 |
Clearstead Advisors, LLC | 55 |
TD Waterhouse Canada Inc. | 9 |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data